Investor Notice: Kessler Topaz Meltzer & Check, LLP Announces Lead Claimant Deadline for November 21, 2022 in Classified Securities Fraud Lawsuit against Fulgent Genetics, Inc.

Radnor, Pennsylvania – () – Law Firm Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent”) (Nasdaq: FLGT). The action charges Fulgent with violations of federal securities laws, including fraudulent omissions and misrepresentations relating to the company’s business, operations, and prospects. As a result of Fulgent’s materially misleading statements and omissions to the public, Fulgent investors suffered significant losses.

click here to send your heavy losses. You can also click the following link or copy and paste into your browser: https://www.ktmc.com/new-cases/fulgent-genetics-inc?utm_source=PR&utm_medium=link&utm_campaign=fulgent&mktm=r

To watch our video, please click here

Deadline for LED Plaintiff: November 21 2022

Study period: March 22, 2019 to August 4, 2022

Contact a lawyer to discuss your rights:

Jonathan Nagy Esq. at (484) 270-1453 or via email at info@ktmc.com

Kessler Topaz is one of the world’s leading advocates for protecting the public from institutional fraud and other wrongdoing. Our securities fraud litigants are regularly recognized as industry leaders individually, and our company is feared and respected between the defense bar and the insurance bar. We are proud to recover billions of dollars for our clients and the classes of shareholders we represent.

Alleged misconduct by FULGENT

Fulgent, along with its subsidiaries, provides COVID-19, molecular diagnostics and genetic testing services to clinicians and patients in the United States and internationally. As a result, Fulgent must comply with federal anti-bribery law, which prohibits the knowing and intentional payment of a “reward” to induce or reward patient referrals or create business involving any item or service payable by federal health care programs. Fulgent must also comply with the Stark Act that prohibits a physician from making referrals of certain certain health services, including laboratory services, covered by Medicare, to an entity with which the physician or an immediate family member has a direct or indirect financial relationship.

On August 4, 2022, Fulgent released its financial results for the second quarter of 2022, revealing, among other things, that the Securities and Exchange Commission was conducting an investigation into certain of the company’s reports submitted to the Securities and Exchange Commission from 2018 through the first quarter of 2020. Followed That disclosure of the Company’s receipt of a civil investigation request issued by the United States Department of Justice “with respect to its investigation of allegations of medically unnecessary laboratory examinations, improper billing of laboratory tests, and awards received or provided in violation of the Anti-Bribery Act and the Stark Act.”

Following this news, Fulgent’s stock fell $11.02 per share, or 17.29%, over the next two trading sessions, to close at $52.72 per share on August 8, 2022.

what can I do?

fulgent Investors may, no later than November 21, 2022, Seeks to be appointed as the Lead Plaintiff’s representative for the Class by Kessler Topaz Meltzer & Check, LLP Or another advisor, or he may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP Fulgent investors who have experienced significant losses are encouraged to contact the company directly for more information.

click here To participate in the cause

Who could be a lead claimant?

The lead plaintiff is a representative party acting on behalf of all members of the class in directing litigation. The principal claimant is usually the investor or a small group of investors who have the greatest financial interest and who are also appropriate and typical of the proposed class of investors. The Lead Plaintiff selects the attorney to represent the Lead Plaintiff and the class and these attorneys, if approved by the Court, are the Lead Counsel or Class Counsel. Your ability to participate in any refund is not affected by the decision of whether or not to serve as lead claimant.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP He litigates class actions in state and federal courts across the country and around the world. The company has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees, and others from fraud, misconduct, misconduct, and negligence by businesses and fiduciaries. The complaint in this procedure has not been submitted before Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP Please visit www.ktmc.com.

Leave a Comment